Frontline Immunotherapy With Response-guided Subsequent Treatment

A Bayesian Causall Analysis of Dose Intensity, Early Benefit and Treatment De-escalation

In this session, Dr. Miller reviews the evolving role of frontline immunotherapy with response-guided subsequent treatment in advanced CSCC. The talk focuses on how early treatment response can inform downstream therapeutic decisions, with an emphasis on optimizing outcomes while minimizing unnecessary toxicity.

Event

University of Louisville Division of Dermatology Grand Rounds Resident Lecture

Overview & Learning Objectives

By the end of this session, participants will be able to:

• Describe the rationale for frontline immunotherapy strategies in advanced CSCC

• Explain the concept of response-guided treatment adaptation and its clinical implications

• Identify opportunities to individualize therapy to balance efficacy and toxicity

This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement